Is meropenem's antibacterial activity dose‑dependent or time‑dependent?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Meropenem is Time-Dependent

Meropenem exhibits time-dependent bactericidal activity, meaning its efficacy depends on maintaining drug concentrations above the minimum inhibitory concentration (MIC) for a sufficient duration of the dosing interval, rather than achieving high peak concentrations.

Pharmacodynamic Mechanism

The FDA label explicitly states that "the percentage of time of a dosing interval that unbound plasma concentration of meropenem exceeds the meropenem minimum inhibitory concentration (MIC) against the infecting organism has been shown to best correlate with efficacy in animal and in vitro models of infection" 11. This is the defining characteristic of time-dependent killing.

The pharmacodynamic target for meropenem is maintaining free drug concentrations above the MIC for approximately 40% of the dosing interval (%fT>MIC ≥ 40%) 12. This stands in contrast to concentration-dependent antibiotics (like aminoglycosides or fluoroquinolones) where peak concentration relative to MIC (Cmax/MIC) or area under the curve (AUC/MIC) are the primary drivers of efficacy.

Clinical Implications for Dosing Strategy

Because meropenem is time-dependent, prolonged or continuous infusions may be superior to standard intermittent bolus dosing, particularly in critically ill patients or when treating organisms with elevated MICs:

Evidence for Prolonged/Continuous Infusion

The French critical care guidelines strongly support this approach. For infections with high MIC bacteria, continuous or prolonged infusions significantly increase the probability of achieving pharmacodynamic targets 3. Specifically:

  • Continuous meropenem 3 g/24h achieved targets for bacteria with MIC ≤ 4 mg/L
  • Intermittent dosing of the same daily dose only achieved targets for MIC ≤ 0.5 mg/L 3

A randomized controlled trial demonstrated that continuous infusion achieved superior microbiological success (90.6% vs 78.4%, P = 0.020) compared to intermittent bolus dosing, with shorter ICU stays and lower total drug requirements 4.

Important Caveats

However, the most recent large-scale evidence (the 2023 MERCY trial with 607 patients) found no difference in the composite outcome of mortality and emergence of resistant bacteria between continuous and intermittent administration 5. This suggests that while continuous infusion optimizes pharmacodynamics theoretically, the clinical benefit may be context-dependent.

Practical Dosing Approach

Standard dosing: 1-2 g IV every 8 hours as 30-minute infusions achieves adequate %fT>MIC for most susceptible organisms 11

Consider prolonged/continuous infusion when:

  • Treating critically ill patients with septic shock 3
  • Suspected or confirmed high MIC organisms (>2-4 mg/L) 3
  • Inadequate clinical response to standard dosing
  • Severe infections in immunocompromised patients 6

The key principle: Unlike dose-dependent antibiotics where you maximize the peak, with meropenem you maximize the time above MIC—either by giving more frequent doses, higher total daily doses, or extending the infusion duration.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.